Associated Banc Corp Sells 3,181 Shares of Johnson & Johnson $JNJ

Associated Banc Corp trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 143,311 shares of the company’s stock after selling 3,181 shares during the quarter. Johnson & Johnson accounts for approximately 0.9% of Associated Banc Corp’s portfolio, making the stock its 26th largest holding. Associated Banc Corp’s holdings in Johnson & Johnson were worth $35,031,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Greenberg Financial Group purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $954,000. World Investment Advisors lifted its stake in Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Johnson & Johnson by 9.8% during the third quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock valued at $17,738,000 after purchasing an additional 8,533 shares during the period. Benchmark Financial LLC bought a new position in Johnson & Johnson during the fourth quarter valued at $554,000. Finally, Sagespring Wealth Partners LLC increased its position in Johnson & Johnson by 6.2% in the fourth quarter. Sagespring Wealth Partners LLC now owns 45,222 shares of the company’s stock worth $9,359,000 after buying an additional 2,660 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.6%

JNJ opened at $253.70 on Wednesday. The firm has a market capitalization of $610.71 billion, a P/E ratio of 29.33, a price-to-earnings-growth ratio of 2.46 and a beta of 0.24. Johnson & Johnson has a one year low of $154.80 and a one year high of $269.43. The company has a fifty day moving average price of $238.18 and a 200-day moving average price of $233.92. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.77 earnings per share. Equities research analysts expect that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts expect Johnson & Johnson to post a solid Q2 print, with commentary pointing to an upbeat report even as Stelara faces headwinds. Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds
• Positive Sentiment: Several preview pieces say JNJ is trading near all-time highs and could still have more upside if earnings and guidance come in strong. Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282
• Positive Sentiment: RBC raised its price target on JNJ to $287 from $265 and maintained an outperform rating, reinforcing bullish sentiment.
• Positive Sentiment: Coverage also highlighted JNJ’s strong year-to-date run and defensive healthcare appeal, which has supported investor demand ahead of earnings. Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.
• Neutral Sentiment: Other articles focused on JNJ as a dividend and income stock, which may support valuation but did not add new material catalysts. How to earn $500 a month from Johnson & Johnson stock ahead of Q2 earnings
• Negative Sentiment: Some commentary noted the stock’s rich valuation after a big rally, suggesting investors may be paying a premium heading into the report. What Lilly’s Peer-Beating Numbers Cost You

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings cut Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. Guggenheim lifted their price objective on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Morgan Stanley boosted their price objective on Johnson & Johnson from $283.00 to $284.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Monday, July 6th. Finally, Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $261.26.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.